SecBot SecBot
SECBOTREPLAY Home › Report › TELA

TELA · TELA Bio reported Q2 2026 revenue of $19.3M, a 4% decline YoY, and an…

TELA Bio, Inc. · 8-K filed Aug 10, 2026 at 16:12 ET

At the news

BEARISHIMPACT 7/10

8-K filed Aug 10, 2026 at 16:12 ET

TELA Bio reported Q2 2026 revenue of $19.3M, a 4% decline YoY, and an EPS of -$0.20, missing consensus estimates of -$0.18. The company withdrew its full-year 2026 revenue guidance, citing a decline in OviTex PRS volumes and ongoing price/mix headwinds. A new CEO was appointed, but the guidance withdrawal and revenue miss signal significant near-term uncertainty and deteriorating fundamentals for this $39M market-cap medical device company.

  • Revenue declined 4% YoY to $19.3M, missing consensus of $20.0M
  • EPS of -$0.20 missed consensus of -$0.18 (-12.4% miss)
  • Full-year 2026 revenue guidance withdrawn, citing OviTex PRS volume decline and competitive bundling pressures
  • Net loss widened to $11.3M from $9.9M in the prior-year quarter

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access